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Foreword 
 
This report has been developed within the NanoReg2 project: "Development and 
implementation of Grouping and Safe-by-Design approaches within regulatory 
frameworks", funded by the Horizon 2020 research and innovation programme of the 
European Union under grant agreement 646221 (http://www.nanoreg2.eu/, 
https://cordis.europa.eu/project/rcn/197088_en.html). 
The report presents the discussions at and contents of the NanoReg2 Regulatory 
Preparedness for Innovation in Nanotechnology Workshop, organised jointly by 
NanoReg2 partners, the National Institute for Public Health and the Environment (RIVM) 
and the Joint Research Centre of the European Commission (JRC), and held in Ispra, 
Italy, 5‒6 October 2017, hosted by the JRC. 
The outcomes of this workshop feed into the Safe Innovation Approach for 
nanotechnology, consisting of Safe-by-Design and Regulatory Preparedness, currently 
being developed by NanoReg2. Furthermore, a paper based on the workshop discussions 
is in preparation. 
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Abstract 
 
This report summarises the presentations and discussions at the first NanoReg2 
Workshop on Regulatory Preparedness for Innovation in Nanotechnology held in Ispra, 
Italy 5 to 6 October 2017 and attended by approximately 60 regulators, industry 
representatives and other stakeholders. NanoReg2 is a European Union (EU) Horizon 
2020 project. At the workshop, Regulatory Preparedness was defined as the regulators' 
timely awareness of innovations and the regulator's actions to check whether present 
legislation covers all safety aspects of each innovation, including initiating revision of the 
legislation as appropriate. Regulatory Preparedness and Safe-by-Design (SbD) jointly 
constitute the NanoReg2 Safe Innovation Approach (SIA) for developing innovative 
products based on nanotechnology. The workshop aimed to gather views and identify 
current practices in regulatory work on safety of innovative products, tools already in use 
or needed, and potential difficulties in implementing Regulatory Preparedness in the EU.  
Presentations addressed the current state of assessing the safety of nanotechnology 
innovations. The viewpoints included the regulatory framework, the principles behind it 
and the agencies and authorities enforcing it; nanosafety research projects and their 
support system (e.g. the current EU Horizon 2020 Framework Programme); national 
nanosafety initiatives; and the development of tools, such as foresight tools and 
harmonised test guidelines by the OECD for data generation. 
The workshop served to generate ideas for achieving Regulatory Preparedness. The 
participants recognised that while regulators deal with the safety of innovations, few 
systematic approaches to this work exist. Some innovative products may reach the 
market before their safety has been appropriately assessed, as illustrated by RAPEX, the 
Rapid Exchange of Information System. A continuous and proactive combination of 
interconnected activities was considered to be required for ensuring Regulatory 
Preparedness. Thus anticipation, e.g. horizon scanning, was seen as important, as was 
communication between regulators, innovators (industry) and other stakeholders. 
Regulators need to become aware of innovative products under development in order to 
ensure that the legislation and methods for safety assessment are available and 
adequate. Innovators must be aware of regulatory requirements and their likely 
development. This mutual awareness helps to develop safe products and to avoid delays 
or other problems in obtaining market approval. Awareness can be achieved through 
communication, which requires trust, promoted e.g. via "trusted environments" for 
confidential inquiries and information sharing. Furthermore, regulators need early access 
to the existing information and data relevant to safety assessment of innovative products 
in order to provide timely guidance and advice to industry as well as to develop 
strategies for dealing with uncertainty, e.g. by applying the precautionary principle. 
Regulatory Preparedness was discussed as part of the SIA, and a "road map" of actions 
was suggested and outlined.  
The workshop has thus contributed towards acceptance of implementing Regulatory 
Preparedness for innovation in nanotechnology through the participation of a variety of 
stakeholders. This paves the way for better dialogue among stakeholders in a fast 
economic development cycle, where it is growingly important to quickly identify emerging 
needs for new approaches to regulatory issues regarding innovation. 
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1 Introduction 
 
Innovation has been defined as "the introduction of something new; a new idea, method, 
or device"(1). More specifically, product innovation has been defined as "the development 
of new products, changes in design of established products, or use of new materials or 
components in the manufacture of established products"(2). While the concept of 
"invention" focuses on new ideas, innovations are generally understood to involve 
transforming ideas into practice to achieve a marketable product(3). Consequently, 
innovators of marketable products are generally associated with the private sector, in 
this report often referred to as "Industry". 
The safety of innovations to human health and the environment is primarily addressed 
through the establishment and enforcement of a regulatory framework, including legal 
acts and related guidance on implementation. The challenges in ensuring the safety of 
innovative technologies and products revolve around the lack of knowledge and 
information about such technologies and products and of existing legislation that applies 
to them. Knowledge of existing technologies and products may not predict issues of 
concern introduced by novel technologies and products. Since innovation typically 
involves an element of surprise, e.g. the particular use/need that the innovation 
addresses, regulatory authorities may not have sufficient information at disposal to 
predict such challenges early enough and thus be able to effectively address them. A lack 
of information and preparedness for the regulatory safety assessment of innovative 
technologies and products can lead either to a delay in an innovative product's 
introduction to the market, or to an innovative product entering the market before its 
safety aspects have been appropriately assessed. Delayed market introduction can 
happen when the product falls under an existing piece of legislation which is not ready to 
tackle the novel safety aspects of the product, which may also result in no safety 
assessment. A lack of safety assessment can also occur when no existing legislation 
explicitly addresses the safety of the product. Obviously factors also need to be in place 
to ensure product safety, e.g. the science and tools need to be ready to provide a solid 
foundation for assessing the safety of innovative products. Additionally, the willingness of 
Industry to share their knowledge of the product could be crucial in having a profound 
understanding of that product, including safety aspects. 
In this report, a regulator is a "regulatory authority or regulatory body (public authority 
or government agency) or representative thereof, responsible for exercising autonomous 
authority over some area of human activity in a regulatory or supervisory capacity"(4), 
while regulation is "the act of regulating; the state of being regulated; an authoritative 
rule dealing with details or procedure (safety regulations); a rule or order issued by an 
executive authority or regulatory agency of a government and having the force of 
law"(5). Examples of regulatory agencies that deal with innovative products include the 
European Chemicals Agency (ECHA), the European Food Safety Authority (EFSA), and the 
U.S. Food and Drug Administration (FDA). Regulators are typically involved in enforcing 
and/or developing legislation within their field of authority. 
The burden of proof regarding the safety (or lack of safety) of a particular innovation 
may be attributed to different actors: usually, this actor is either the industry producing 
the innovative product or the regulator under whose jurisdiction the product falls. This 
depends on the regulatory framework, which in turn depends on both the political 
infrastructure, such as the European Union, and on the particular type of product or 
technology involved, which may or may not be covered by existing specific safety 
legislation. Even in cases where there is no dedicated safety regulation addressing a 
                                           
(1)  Merriam-Webster; https://www.merriam-webster.com/dictionary/innovation 
(2)  Policy Studies Institute, University of Westminster; http://www.psi.org.uk/publications/archivepdfs/ 
Small%20firms/SF1.pdf 
(3)  Business Dictionary; http://www.businessdictionary.com/definition/innovation.html 
(4)  Wikipedia; https://en.wikipedia.org/wiki/Regulatory_agency 
(5)  Merriam-Webster; https://www.merriam-webster.com/dictionary/regulation 
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certain product, scenarios exist for prompting a safety assessment. For example, 
regulators may identify possible areas of concern or stakeholders, such as non-
governmental consumer or environmental protection organisations, or simply public 
attention, apply pressure that leads to the closer inspection of the safety of an innovative 
product or technology and possibly to changes in legislation. 
Consequently, the precise role of regulators in the safety assessment of innovative 
products varies. Regulators may need to assess the safety of an innovation, such as 
nanotechnology, on a general level in order to determine whether it requires closer 
attention or whether the applicable legislation needs to be modified to properly address 
the innovation. Some regulators may need to perform product-specific safety assessment 
on the basis of the information provided by Industry or available from the literature. 
Regulators may also fund or even perform research that produces information or 
methodologies for the safety assessment of an innovation. Regulators also commonly 
provide guidance to Industry for complying with regulatory requirements, in the form of 
documents or by answering direct questions posed by Industry. 
The NanoReg2 project(6) is developing a Safe Innovation Approach (SIA) which combines 
the Safe-by-Design (SbD) concept, applied by Industry to include safety considerations 
from the early stages of the development process of an innovative product, and 
Regulatory Preparedness (RP), which aims to help regulators to become aware of 
relevant, i.e. upcoming or already in use, innovations and to develop the regulatory 
framework, requirements and methodology accordingly. The fully developed SIA will thus 
help Industry to produce safe innovative products and to provide appropriate safety-
related information about them, as well as the regulators to be prepared for addressing 
regulatory safety assessment needs without delay. While NanoReg2 focusses on the 
safety assessment of manufactured nanomaterials (MNMs), SIA as such is not restricted 
to nanotechnology but can apply to all innovative technologies and products.  
The NanoReg2 Regulatory Preparedness for Innovation in Nanotechnology Workshop for 
discussing the practical aspects of regulatory preparedness for the risk assessment of 
nanotechnology innovations, and innovations in general, was organised jointly by the 
NanoReg2 partners, the National Institute for Public Health and the Environment (RIVM) 
and the Joint Research Centre of the European Commission (JRC) in Ispra, Italy, 5‒6 
October 2017. This report summarises the presentations given, the break-out group 
discussions among the participants (listed in Annex 4) and the conclusions presented by 
the participants at the workshop. 
                                           
(6)  http://www.nanoreg2.eu/ 
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2 Workshop presentations 
 
2.1 Day 1: Welcome and setting the scene 
 
2.1.1 Welcome by workshop hosting institution  
Elke Anklam, Joint Research Centre (European Commission) 
The director of JRC Directorate F - Health, Consumers and Reference Materials welcomed 
the participants to the workshop, with an introduction to the activities of this host 
institution in the field of nanosafety. 
 
2.1.2 Introduction to NanoReg2  
Emeric Frejafon  
Institut national de l'environnement industriel et des risques (INERIS), France 
The coordinator of the NanoReg2 project gave an overview of this Horizon 2020 project 
and its aims and outcomes. The purpose of NanoReg2 is to develop and implement 
Grouping and SbD approaches that can be used in a regulatory context. The duration of 
NanoReg2 is 36 months from September 2015 to 2018, and it has 42 partners from 16 
EU Member States (MSs) or associated countries. 
The specific objectives of NanoReg2 are to compile regulatory driven tools for assessing 
aspects of the safety of nanomaterials (NMs), and develop grouping approaches and 
Intelligent Testing Strategies based on data management tools. This should result in 
achieving robust information on safety requirements of an innovation along its value 
chain. An important project component is to propose a Safe(r)-by-Design principle and 
outline how regulatory preparedness can be addressed, aiming to ensure: safe products, 
safe production and safe use. NanoReg2 should also lead to a SIA toolbox, whose 
applicability should be demonstrated with industrial case studies, showing gains achieved 
on safety. Finally, information on NanoReg2 and results achieved should be disseminated 
to all stakeholders, notably to the OECD, the European Committee for Standardization 
(CEN) and the International Organization for Standardization (ISO) and through Public-
Private Partnerships for example for pre-validation capabilities of regulatory driven tools. 
Within NanoReg2 a grouping approach, elaborating the MARINA approach and combining 
it with knowledge of NANoREG(7) and NanoReg2 needs, has been developed, reflecting 
the three questions i) What they are?, ii) Where they go? and iii) What they do? An 
important source of information for validating the grouping approach is the NanoReg2 
database that consolidates earlier experimental data (NANoREG, MARINA(8), 
NanoTEST(9) and Nanogenotox(10)) and contains information from more than 6000 
experiments regarding physical-chemical properties, (eco)toxicology and environmental 
fate. 
 
  
                                           
(7)  https://www.rivm.nl/en/About_RIVM/Mission_and_strategy/International_Affairs/International_Projects/ 
Completed/NANoREG 
(8)  http://www.marina-fp7.eu/ 
(9)  http://www.nanotest-fp7.eu/ 
(10)  https://www.anses.fr/fr/node/120284 
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2.1.3 Scope and objectives of the workshop  
Lya G. Soeteman-Hernández & Cornelle Noorlander  
Centre for Safety of Substances and Products, National Institute for Public Health and the 
Environment (RIVM), Bilthoven, the Netherlands 
The Regulatory Preparedness (RP) concept, as being developed in the European project 
NanoReg2, aims to improve the anticipation of regulators so that they can facilitate the 
development of adaptable (safety) regulation that can keep up with the pace of 
knowledge generation and innovation of MNMs and MNM-containing products. In order to 
achieve this, regulators need to be prepared by being aware of new materials, 
technologies and innovations in the early stage of the innovation process. Information 
about the scientific state-of-the-art and innovations is needed in order to timely check on 
whether current regulations cover all aspects of innovation to ensure human and 
environmental safety. RP is needed in order for regulators and policy-makers to keep up 
with the exponential pace of technological change and to ensure the human and 
environmental safety of innovative emerging technologies such as (novel) MNMs and 
products containing them. 
In order for safety regulators to keep up with innovations, they need to transition from a 
reactive to a proactive role. This means that even though in many instances Industry is 
responsible for the safety of their products, regulators need to be pro-active in keeping 
up-to-date with new innovations and be engaged in dialogue with innovators and 
Industry for knowledge sharing with regards to how to deal with new developments and 
limited insight on how nanospecific characteristics influence human and environmental 
toxicity. Finally, regulators may support efforts to translate this knowledge into policy in 
an efficient and timely manner. 
The objective of the workshop was to have open discussions with various regulatory 
bodies about the regulatory challenges with regards to new nanotechnology innovations 
including: 
1) Inventory of views on the role of safety policies and regulations in innovation 
2) Common understanding of RP concept 
3) Awareness and consensus for the need for RP 
4) Insight on regulator’s needs to be prepared for innovations 
5) Identify the potential tools needed to achieve RP 
6) Gaining insight on the incentives and barriers surrounding RP 
 
2.2 Day 1: Regulatory context 
 
2.2.1 The need for Regulatory Preparedness  
Georgios Katalagarianakis 
European Commission, DG Research & Innovation (DG RTD), Brussels, Belgium 
Horizon 2020 (H2020)(11) aims at supporting research in the EU to achieve Leadership in 
Enabling and Industrial Technologies (LEIT)(12), thus supporting Key Enabling 
Technologies (KETs)(13) for European growth. The presentation explained how H2020 
supports KETs in nanotechnology, and that one of the innovation principles is safety, 
                                           
(11)  https://ec.europa.eu/programmes/horizon2020/ 
(12)  http://ec.europa.eu/programmes/horizon2020/en/h2020-section/leadership-enabling-and-industrial-
technologies 
(13)  http://ec.europa.eu/growth/industry/policy/key-enabling-technologies_en 
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which is indirectly addressed in EU legislation but very present in everyday life, and 
safety in itself needs innovation as well as rules (e.g. no data – no market).  
When regulating technologies, one aim is to ensure that known and quantified risks stay 
below a defined maximum acceptable level. Currently, the application of SbD to NMs as a 
means of reducing unacceptably high known risks and for engineering-out known but not 
quantified risks is analysed. Furthermore, the need for safe products is underpinned by 
the precautionary principle, which is closely linked to governance, including risk 
governance. Governance is focused on converting knowledge (including limited 
knowledge) into choice (including the choice not to choose) and converting choice into 
action (including the choice of not to act) towards a goal. It thus primarily consists of 
defining a (set of) goal(s), and then being able to implement policies towards the goal 
and take action on i) Information, ii) Communication, iii) Planning and Feedback, and iv) 
Progress Monitoring, for all of which we need a high degree of preparedness, which is at 
the moment lacking in varying degrees. 
The main directions for the upcoming five Nanotechnologies, Advanced Materials, 
Biotechnology and Advanced Manufacturing and Processing (NMBP)(14) calls 2018‒2020 
are towards the integration of scientific, regulatory and market phases, as well as civil 
society for governance, while encouraging international cooperation. 
 
2.2.2 Nanomaterials in food: regulation and innovation  
Takis Daskaleros 
European Commission, Health and Food Safety Directorate General (DG SANTE), Food 
processing technologies and novel foods Unit, Brussels, Belgium 
The need to ensure harmony between regulation and innovation is pertinent to all 
cutting-edge technologies, including nanotechnology and its applications in the food 
sector. Regulatory Preparedness, Safety-by-Design of NMs and upstream communication 
are among the key factors contributing to addressing this need.  
The EU is the only region in the world which has specific requirements for 
nanotechnology and NMs in its legislation. Existing regulations on novel foods, food 
contact materials and food additives require a case-by-case assessment of applications 
containing NMs, while the legislation on the provision of food information to consumers 
requires the appropriate labelling of food ingredients at the nanoscale.  
This presentation illustrated how the use of NMs in food products is addressed in the EU 
through a consolidated legal framework which ensures proper functioning of the market, 
a high level of safety, transparency and clarity for economic operators, and meeting 
consumer and societal expectations. This framework is supported by a science-based 
definition, continuing work on risk assessment performed by the EFSA and appropriate 
enforcement.  
The presentation also discussed the prospects of and the dynamic relationship between 
regulation and innovation and proposes a number of elements which may help both 
regulation to proactively adapt to innovation and innovation to feed early on to 
regulation, for example innovation foresight, knowledge sharing, integration of safety 
aspects in the early stages of innovation, and regulatory vigilance and preparedness. 
 
  
                                           
(14)  http://ec.europa.eu/programmes/horizon2020/en/h2020-section/nanotechnologies-advanced-materials-
advanced-manufacturing-and-processing-and 
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2.2.3 An example of being prepared for innovations in food  
Reinhilde Schoonjans  
Scientific Committee and Emerging Risks Unit, European Food Safety Authority (EFSA), 
Parma, Italy 
Substances to be used in agricultural, food and feed products are subject to scientific risk 
evaluation. This is part of the regulatory context for safe food in Europe. For innovations 
such as NMs in the food chain, refinements in the regulatory context ensure that specific 
health concerns can be addressed during risk assessment. It is the EFSA that provides 
scientific risk assessment advice to the European Commission and MSs, who decide on 
the authorisation as risk managers. Since 2009, EFSA has been preparing for adequate 
risk assessment for NMs with a number of actions. 
To reach innovators and inform them about the required safety testing for human and 
animal health, the EFSA guidance for risk assessment was published in 2011(15). This 
document outlines the nano-specific characteristics that need to be measured and how 
subsequent testing might be adjusted to take the nano-properties into account. This 
guidance is currently being updated(16).  
As a following step Environmental Risk Assessment Guidance will be developed to cover 
also the environmental fate and impact of e.g. NMs used in plant protection products. 
In 2014(17), an information survey revealed what type of NMs and what type of 
applications can be expected for the food and feed chain. The main areas of application, 
relevant for EFSA, are food contact materials, food additives, feed additives, novel food 
and pesticides.  
The activities by EFSA build on networking (e.g. with external experts, MS delegates(18), 
JRC, ECHA, OECD) and on existing experience (e.g. from European Research projects 
such as NANoREG, NanoDefine(19), NanoLyse(20)). 
 
2.2.4 OECD's approach to the safety of nanomaterials: lessons learned 
for regulatory preparedness and future innovation  
Peter Kearns & Mar Gonzalez  
Organisation for Economic Co-operation and Development (OECD), Working Party on 
Manufactured Nanomaterials (WPMN) 
The OECD has an important role in addressing regulatory needs for the safety 
assessment of chemicals by ensuring the availability of internationally agreed Test 
Guidelines (TGs), which currently number about 150. Through OECD's system of Mutual 
Acceptance of Data (MAD), duplication of work is avoided as "data generated in the 
testing of chemicals in an OECD Member country in accordance with OECD TGs and OECD 
Principles of Good Laboratory Practice (GLP) shall be accepted in other Member countries 
for purposes of assessment and other uses relating to the protection of man and the 
environment". Thus testing needs not to be repeated, however, interpretation of test 
results is the prerogative of national authorities. GLP is a quality system that ensures 
data quality and thus the longer term validity of the testing. 
The OECD chemicals programme started more than 40 years ago, providing a forum for 
policy dialogue and development of policies for obtaining safer chemicals. The chemicals 
                                           
(15)  EFSA Scientific Committee; Scientific Opinion on Guidance on the risk assessment of the application of 
nanoscience and nanotechnologies in the food and feed chain. EFSA Journal 2011;9(5):2140. Available 
online: http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2140/full 
(16) Published in 2018 at https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2018.5327 
(17)  http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/621e.pdf 
(18)  http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/939e.pdf 
(19)  http://www.nanodefine.eu/ 
(20)  http://www.nanolyse.eu/ 
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programme has helped identify regulatory needs of countries, leading also to global 
convergence by facilitating harmonised practices and standards, and by recommending 
policies. Furthermore it has provided a forum for information exchange, including data for 
use in risk assessment as well as the methods to collect such data. 
The Nanosafety Programme(21), like the WPMN, dates from 2006 and thus is a more 
recent addition to the chemicals programme. It is a model for addressing regulatory 
awareness and preparedness toward safety policies for emerging technologies. The 
WPMN promotes international co-operation amongst countries on the human health and 
environmental safety aspects of MNMs for regulatory purposes.  
The Nanosafety Programme ensures the provision of knowledge and information by 
identifying the needs for TGs, sharing risk assessment approaches, and identifying 
potential exposure for worker, consumers and the environment to NMs. Further insights 
are obtained via case studies, e.g. on NMs in tyres. Based on this knowledge the 
Programme can offer assistance with governance in the form of TGs and Guidance 
Documents (GDs). This also provides support for capacity building, via collaboration with 
other Intergovernmental Organisations, in particular those from the Inter-Organization 
Programme for the Sound Management of Chemicals (IOMC) (e.g. United Nations 
Institute for Training and Research, UNITAR). The Programme facilitates risk reduction by 
exploring adverse outcome pathways (AOPs), grouping/category and read-across 
approaches; also specific guidance for addressing physical-chemical properties of NMs in 
the absence of TGs is under development.  
The incorporation of NMs into existing systems for addressing the safety of chemicals is 
built on comparing and analysing existing approaches to safety with emerging 
approaches, resulting in a flexible programme to address emerging issues.  
 
2.2.5 Ongoing French regulatory or pre-regulatory initiatives 
Damien De Geeter 
Ministère de la Transition écologique et solidaire, France 
Two examples of French regulatory initiatives were exposed during the presentation: 
1. the French nano substances registry "R-Nano" 
The idea to register nano substances was expressed first during a large national 
public debate called "Grenelle of environment" which took place in 2007, followed 2 
years later by another national public debate dedicated to nanotechnologies. 
Afterward, the principle of the registry has been recorded in the law, before starting 
in 2013. There was a need expressed by civil society and actions in the law in 
response. But it has been debated for a long time. 
The database(22) gives the traceability of each substance and improves risk 
assessment by providing additional data to scientific research. The registry also 
improves information and makes communication to the public easier. For 
confidentiality reasons, only a few entities are allowed to access data linked to their 
researches only. The registry is also used for choosing and controlling factories. 
Registrants are: producers, importers to French territory (based on any states 
including other European MSs), distributors to "the last professional user" of the 
substance. They have to declare from 100 grams of substance. For example the 
report published last year concerning data from 2015 shows there are around 1 500 
declarations and 500 000 tons on the French market. 
After five years the number of declarations seems stable. Regarding uses and 
substances, a substance could be declared by lots of users, but it doesn't mean this 
                                           
(21)  http://www.oecd.org/science/nanosafety/ 
(22)  https://www.r-nano.fr/ 
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substance has been used in big quantities. The profile of registrants is also very 
variable. 
 
2. the French 2017 guideline "best practices for using nano substances in 
industry" 
The purpose of the guideline(23) is to start discussing NMs in Industry. To write the 
guideline, a taskforce has been created and some French environmental inspectors 
visited 11 French registrants in R-nano database with various profiles (not just big 
industries), before going to the USA in order to compare practices. 
The guideline has been made for inspectors and companies, and contains 
organization, equipment that can be used in facilities: usual and accidental situations, 
air and water release, waste management, storage, transfer and packaging of the 
nano substances. All equipment is described, with advantages and sometimes costs. 
Environmental inspectors can compare practices with the one described in the 
guideline. Companies must explain if they proceed differently and justify they reach 
the same result. Concerning the guideline, the appropriate policy is to adapt what we 
require regarding the risk assessment of the substance concerned. During controls, 
environmental inspectors assess the practices, the organization etc. and compare 
with the guideline. 
The guideline is focused on environmental protection, not workers, and some of 
principles are similar as dusty release prevention. 
These two French initiatives were built with stakeholders. For nanotechnologies, the first 
step is to identify innovations. Then it is important to preserve environment and human 
health, so science knowledge and research are also necessary. That is why the French 
registry was created: to know substances, uses, quantities… And a law was necessary for 
that. Progressive regulation like the French guideline is also a good way to legislate. In 
this way, companies progressively understand the objectives of regulations, and can 
prepare themselves to respect laws. 
 
2.2.6 Safe Innovation Approach  
Lya G. Soeteman-Hernández & Cornelle Noorlander 
Centre for Safety of Substances and Products, National Institute for Public Health and the 
Environment (RIVM), Bilthoven, the Netherlands 
Technological innovations are developing at such a dynamic pace that they pose a 
challenge to governance of public and environmental safety due to the large difference in 
the pace between innovation and the development of suited governance. Nanotechnology 
innovation is an example where the pace by which innovative materials and products is 
developed exceeds the generation of knowledge required to sufficiently address the 
safety of these materials and their products. With the Safe Innovation Approach (SIA), 
under development within the EU project NanoReg2, we look for ways to enhance the 
ability of all stakeholders to create robust, yet flexible processes of integrating the safety 
evaluation in the innovation. SIA is an approach that combines a) the Safe by Design 
(SbD) concept, and b) the Regulatory Preparedness (RP) concept. The SbD concept aims 
at reducing uncertainties and risks of human and environmental safety, starting at an 
early phase of the innovation process and covering the whole innovation value chain. The 
RP concept aims for regulators to be prepared for innovations. SIA promotes a safe and 
responsible approach for companies working on the development of innovative products 
and materials and stimulates a proactive attitude amongst policymakers or regulators to 
ensure that regulations keep up with the pace of innovations. SIA should lead to a 
                                           
(23)  https://www.ecologique-solidaire.gouv.fr/nanomateriaux 
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resilient process which has the ability to anticipate, learn about and adapt to 
technological innovations. 
 
2.3 Day 2: Tools for regulatory preparedness 
 
2.3.1 Towards a framework of policy assessment of emerging 
technologies  
Steffi Friedrichs 
Organisation for Economic Co-operation and Development (OECD), Working Party on 
Biotechnology, Nanotechnology and Converging Technologies (BNCT) 
An emerging technology is a largely unknown technology with unknown impact on the 
society, the economy, or the environment and unknown potential for public acceptance, 
misuse or discrimination. Assessing the policy implications of an emerging technology is 
therefore a challenge that needs to be addressed in view of the Next Production 
Revolution based on advanced materials, including NMs. 
To understand and accommodate rapid technological advancements, the BNCT developed 
a flexible Framework for Future Policy Assessment. The approach is based on 2 tiers: Tier 
1 combines technology assessment and foresight assessment; Tier 2 combines policy 
assessment and policy backcasting. For each tier, a proof-of-principle workshop is 
organised.  
The presentation gave an overview on the OECD BNCT framework and illustrated the 
results of the Tier 1 multi-stakeholder workshop organised on 15‒16 May 2017 in 
Brussels and focused on 3D-printing of human body parts as case-study. At the 
workshop, participants were guided through a series of activities starting from the 
scenario description based on attributes to the identification of policies that need to be 
adapted. The testing of the Tier 1 approach was positive but also provided advice on 
improvements. Another workshop will be held in 2018 to test the Tier 2 approach. 
 
2.3.2 Impact of precautionary regulation on innovation processes  
David Azoulay  
Center for International Environmental Law (CIEL), Geneva, Switzerland 
The presentation aimed at exploring the relationship between precaution, regulation and 
innovation. It started with a word of caution about using innovation as value in and of 
itself, arguing that for innovation to truly benefit society as a whole, it needs to be 
guided.  
Going back specifically to NMs, the question of uncertainty was presented as a critical 
element of any discussion on nano regulation and management, and two distinct types of 
uncertainty were identified: scientific uncertainty, which is an integral part of any 
technological innovation and which will endure, and legal uncertainty, which is a serious 
obstacle to technological innovation processes, and is extremely costly both to Industry 
and regulators. 
While scientific uncertainty cannot be eliminated, it is technically possible to do away 
with legal uncertainty, by using the precautionary principles and precaution based 
regulation. Precaution-based regulation is often accused of hampering innovation, but is 
that really the case? The last part of the presentation focuses on presenting a CIEL study 
that looked specifically into this question. 
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We first note that while there are many historical examples where ignoring precautionary 
approaches have led to serious health and environmental impacts (asbestos, benzene, 
lead etc.), there are no documented instances where regulation prevented a 
technological innovation from reaching the market. 
CIEL has looked at the particular case of phthalates (common plasticizers, with endocrine 
disrupting effects, classified as a suspected carcinogen with links to diabetes, obesity 
etc.) and specifically at the impact of legislation restricting the use of phthalates starting 
in the late 90s. CIEL used patent families as an indicator of rate of innovation in the field 
impacted by the legislation. The study clearly shows that every restriction of the used of 
phthalates saw a spike in the number of patents for phthalate-free inventions and 
inventions that can use either phthalates or non-phthalates.  
In addition, the study showed that most patented inventions for non-phthalates products 
(as disclosed in patent filings between 1972 and 2011) went beyond just those product 
classes initially singled out by legislation (mainly toys and childcare products). 
The presentation concluded that while innovation is indeed being changed by regulation, 
there is a redirection of innovative efforts into more socially approved areas rather than 
an absolute decline. Regulation based on health and environmental precaution not only 
creates a safer market place but also drives innovation. 
 
2.3.3 NANoREG Foresight System  
Christian Micheletti  
EcamRicert Srl, Monte di Malo, Vicenza, Italy (now TEMAS AG, Switzerland) 
Technological innovation is accelerating its pace. Modern technology is changing our lives 
more and more, and it is difficult to deal with all the changes from a societal and 
regulatory point of view. Technologies like Artificial Intelligence, Human Augmentation, 
Autonomous Vehicles, while still not commercially available, they are all posing ethical 
and economic issues right now. Nanotechnology, being a key enabling technology, is 
potentially part of all incremental and revolutionary innovations of our times, and it 
needs to be governed.  
Governance of nanotechnology innovation in the NANoREG project context was translated 
as regulatory preparedness, i.e. making regulators aware of new technologies, and giving 
them the time to act, e.g. via hard and soft regulations as well as targeted research and 
development (R&D) funds. One important piece of the regulatory preparedness is to 
assess the impacts on Health, Safety and Environment (HSE) of technological 
development early on, i.e. with a time-to-market of 5‒10 years.  
The NANoREG Foresight System proposes a platform dedicated to regulators, allowing 
the adverse impact assessment of new potential applications of NMs. The first step of the 
platform is the identification of Target Applications (TA). TAs are relevant nanotechnology 
applications, related to a specific NM (e.g. graphene), a specific application (e.g. 
photovoltaics), or a specific industry sector (e.g. automotive). The starting point is the 
"General Concern", which is the translation of the societal concern as viewed by 
regulators. An example of this input can be the European Parliament Foresight of 
emerging technologies. From the General Concern, through the three different entry 
points, a list of applications is identified by looking at different sources of information: 
internet-based (e.g. tweeter), people-based (e.g. workshops), science-based (e.g. 
scientific literature) and market-based (e.g. market studies, patents). The answer that is 
expected is which the main relevant applications are, in terms of specific criteria such as: 
widespread use, economic and/or strategic interests, potential benefits, public concern.  
Once the TAs are identified, for each one of them an impact assessment is performed. 
While in the NANoREG Foresight System a Preliminary Risk Assessment approach is 
proposed, with the definition of qualitative risk hypotheses, nothing prohibits the use of a 
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Life Cycle Assessment (LCA), or other tools to qualitatively define impacts on HSE. 
Finally, to illustrate how the System works, a case study on graphene was developed, 
focusing on water treatment membranes, availability of clean and safe water being one 
of the main topics of the following years. 
 
2.3.4 White Paper implications for Regulatory Preparedness  
Tom van Teunenbroek, Dutch Ministry of Infrastructure and the Environment 
The White Paper(24), which was drafted by the Project Office of the ProSafe project(25) 
and thus does not necessarily reflect the opinion of Partners and Management 
Committee, is a non-paper that aims at integrating the results from the NANoREG and 
ProSafe projects. A further aim of the White Paper is to translate these results into 
recommendations for policymakers, regulators and organisations funding nanosafety 
research to achieve a more efficient/effective governance of nanosafety. One issue is that 
the increasing complexity of NMs requires an adaptable testing strategy for assessing NM 
fate and toxicity. NANoREG and ProSafe provided input to (partially) address (some of) 
the hurdles for an effective and efficient governance and regulation of NMs. These 
hurdles can be divided into i) technical/scientific "problems": e.g. (standard) test 
methods are missing or not applicable for NMs, ii) infrastructure for data management 
not adequate, e.g. nanoEHS data often not accessible or fit for further evaluation, the 
data quality is uncertain and there are no facilities for checking or curation, and iii) 
regulation (REACH) usually having chemical identity as entry point, generic information 
requirements and a hazard oriented approach which are not suited for NMs. 
The White Paper gives recommendations on how to address these issues, e.g. by 
intensifying the OECD TG programme; consolidation/implementation of the eNanoMapper 
infrastructure from NANoREG for data management, combined with an obligation to 
share results of publicly funded nanosafety research projects, establishing structural 
facilities for storing standardised nano EHS data and further development of ontology and 
data curation. Also mining and generation of "quality nanoEHS data" for SbD, read 
across, etc. is proposed. Furthermore, the legal basis for the definition of NMs should be 
included in REACH(26) and the data requirements should be adjusted for NMs. Innovation 
in risk assessment is also an aspect that will help understanding the effects of NMs, e.g. 
through creation of a more fundamental understanding of the mechanisms causing 
adverse effects (Modes of Action (MoAs); AOPs) and through development of cheaper 
and faster test methods like in vitro High Throughput Screening (HTS) and in silico 
methods. Ways of making the approach future-proof should be explored. 
                                           
(24) https://www.rivm.nl/en/About_RIVM/Mission_and_strategy/International_Affairs/International_Projects/ 
Completed/ProSafe/ProSafe_White_Paper 
(25)  https://www.rivm.nl/en/About_RIVM/Mission_and_strategy/International_Affairs/International_Projects/ 
Completed/ProSafe 
(26) https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32006R1907  
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3 Break-out groups 
 
Each of the four topics was discussed in four parallel break-out groups. The workshop 
participants were assigned into these four groups by the organisers in order to achieve a 
balanced representation of regulators and Industry in each group. The following 
summaries cover the main points of the discussions in all of the parallel groups, moving 
them under the appropriate topic where necessary and leaving out the points clearly 
outside the scope of the workshop. 
Since this is the first workshop on Regulatory Preparedness concept as a part of the Safe 
Innovation Approach, the discussions were informal and aimed at outlining the status 
quo, views, ideas and potential difficulties. Therefore, all the relevant contributions to the 
discussion (according to rapporteur notes) have been included, and no general consensus 
among the workshop participants on the various specific points should be assumed. 
Where possible, clarification in the form of practical examples, larger context, etc. is 
provided. 
 
3.1 Day 1: Regulators and innovations: the status quo and needs  
 
3.1.1 How do regulators currently deal with innovations?  
3.1.1.1 General remarks 
According to the participants, overall, regulators currently have few systematic 
approaches to dealing with innovations in practice. Typically, innovations were reacted to 
on a case-by-case basis as they materialise, later resulting in legislation that addresses 
underlying issues for the future, e.g. the Directive 67/548/EEC(27) that attempts to 
address hazards of general chemicals in the wake of several examples of disregarded 
adverse effects of chemicals(28). The Directive is the first version of legislation addressing 
dangerous chemicals in general that are currently regulated by REACH(26). Another 
example is the Seveso Directive(29) that was agreed in the aftermath of three industrial 
accidents (30, 31, 32) to prevent similar accidents and ensure information to the general 
public. In order to avoid unnecessary delay in bringing innovative products to the market 
but on the other hand to properly assess the safety of such products and avoid possible 
adverse effects on human health and/or the environment, regulators should be able to 
anticipate future safety assessment needs and prepare for them. One of the challenges is 
the lack of information connected with innovative products: do hazards and exposures 
need to be fully known before risks can be predicted and, if necessary, reduced to an 
acceptable level through legislation, and to what extent can the precautionary principle 
be applied? 
Interaction between the different actors helps the regulators to anticipate what is coming 
(and prepare for it) and Industry to understand how the regulators handle innovations. 
Such interaction also promotes the passing of the information needed for safety 
                                           
(27) https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:31967L0548 
(28) https://www.eea.europa.eu/publications/environmental_issue_report_2001_22/Issue_Report_No_22.pdf/ 
view  
(29) https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32012L0018 
(30) https://www.icheme.org/communities/special-interest-groups/safety and loss prevention/resources/~/ 
media/Documents/Subject Groups/Safety_Loss_Prevention/HSE Accident Reports/The Flixborough Disaster 
- Report of the Court of Inquiry.pdf 
(31) https://www.statoquotidiano.it/18/09/2012/indagini-epidemiologiche-17-sin-bibliografia-per-manfredonia/ 
99724/ 
(32) http://www.icheme.org/shop/lpb/2013/major-process-incidents-1-resource-pack/the seveso disaster - an 
appraisal of its causes and circumstances.aspx  
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assessment from innovators to regulators. However, interaction is currently made 
difficult by both mutual lack of understanding and reluctance by innovators to share 
information on the science that underpins an innovation, since sharing this information 
may lead to loss of control of the innovation and the potential financial profit from it. 
3.1.1.2 How regulators become aware of innovations and their risks/hazards 
A common starting point for regulators to deal with an innovation is encountering a new 
type of product about which key information related to safety seems to be missing. The 
general principle then is to start by gathering information about the innovation: What is it 
about, and what about it is new and different? Does is fit within the existing safety 
regulations (and if so, where), or are there significant gaps in the regulations? 
Awareness may be a result of collaboration e.g. among regulatory bodies, with non-
governmental organisations (NGOs) or internationally within the academia, the European 
Union, the OECD, etc. Also Industry may raise awareness. Another possible source of 
information leading to awareness is the (legally required) registration of substances or 
products and their uses by Industry, including requirements of any pre-commercialisation 
testing or product description, where applicable. 
As individuals, regulators may attend various sorts of conferences, workshops and 
meetings (for either experts or stakeholders) in order to become and stay informed of 
relevant innovations. Systematic screening tools and e.g. the EU RAPEX system (Rapid 
Alert System for dangerous non-food products(33) are other means of learning about 
innovations and upcoming issues.  
At the institutional level, the current way of dealing with innovations seems to depend 
largely on the specific sector. For instance, in the thoroughly regulated medical sector, 
the industry typically approach regulators at an early stage of the innovation process to 
discuss regulatory matters and minimise the new product's time to market. Some 
institutions organise regular meetings with the different stakeholders (i.e. policy makers, 
regulators and industry) for the purpose of discussing innovations.  
For horizon scanning needs at the level of policy and decision making, the Directorate-
General for Parliamentary Research Service (DG EPRS) of the European Commission has 
developed a guiding framework for technology foresight which aims to cover Social, 
Technological, Economic, Environmental, Political/legal, Ethical and Demographic 
(STEEPED) aspects(34).  
Information is gathered by performing literature searches and by means of calls for data 
from interested parties. It should be noted that while Industry may have produced data 
relevant to the safety of the product, the need to protect their intellectual property often 
makes them reluctant to share it.  
If the regulators face pressure in the form of e.g. extensive media or public attention, the 
safety assessment of a certain innovation may be prioritised and stakeholder 
consultations may be held. However, the amount of media attention that an innovation 
has attracted may not as such be a good indicator of whether or not its safety actually 
requires more regulatory attention; it may rather indicate a need for better 
communication between regulators and the public. Communication with the general 
public and consulting stakeholders are good practice in innovation processes in general, 
but consultation is not a fail-proof approach, as seen e.g. in the case of genetically 
modified organisms (GMOs). The results of such consultations tend to depend on the 
amount of media interest, which in turn depends largely on what else happens to be 
competing for this interest at the time. 
                                           
(33) https://ec.europa.eu/consumers/consumers_safety/safety_products/rapex/alerts/repository/content/ 
pages/rapex/index_en.htm 
(34) http://www.europarl.europa.eu/RegData/etudes/IDAN/2015/527415/EPRS_IDA%282015%29527412_ 
REV1_EN.pdf; http://euspri-vienna2017.org/wp-content/uploads/2017/05/ExAB-46-Friedrichs-Evaluating-
the-Impact-of-Convergence.pdf 
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3.1.1.3 How regulators assess the risk of innovations 
Regulators typically start assessing the safety of innovations when the need arises (the 
trigger being that it is a regulatory requirement, or missing knowledge or, in some cases, 
risks/hazards discovered through incidents) and by doing their best with what they have. 
When several cases of similar new technology have come to light(35), fact-finding and 
broader discussion takes place. In the meanwhile, the relevant industry can be 
supported, e.g. through legal information requirements or reports on lessons learnt, with 
precautionary measures to improve awareness of potential safety issues and provide 
pragmatic instruments for dealing with them. 
Also novel types of products require a risk assessment process. In order to understand 
how to assess the risk of such products, regulators need a fact-finding process (which 
often involves asking for information from the producer) and in general to "ask more 
questions". This may be complicated by the lack of clarity on what kind of questions 
should be asked in each particular case. Regulators can also request and fund research 
that is aimed at identifying problems from contractors, such as academic institutions and 
national institutes, and interact with various stakeholders to handle the situation.  
As an example, many governments started to look relatively early on into the safety 
issues of nanotechnology and in particular to collect information. OECD's work on the 
safety of NMs started with governments contacting the OECD to ask how to handle the 
safety assessment of NMs. 
3.1.1.4 Promoting the safety in innovation 
Regulators can also influence the safety of innovations by promoting safe technology. In 
R&D work, exploration is clearly needed. On the other hand, both the occupational safety 
of the researchers involved and the safety of the eventual products need to be 
considered, and here the many unknowns of innovative activities are a problem. In 
publicly funded research, safety measures in the form of SbD or other relevant 
approaches are generally required; private companies may be less precautionary. 
 
3.1.2 What do regulators need to be prepared for innovations?  
3.1.2.1 General remarks 
The general regulatory process of dealing with an innovation starts with awareness and 
passes through the development of the necessary methodology to acquire the 
information to perform the actual risk (safety) assessment. However, different insights 
need to be combined in regulatory work, and ideally, the big picture is always looked at: 
the safety of the innovative product weighed against its contribution to society in e.g. the 
form of jobs and other benefits that the innovation promises to bring; circular economy, 
life cycle and waste management considerations; and uncertainty in its various forms. 
It was generally agreed that proactive approaches – looking into the future by e.g. 
keeping an eye on trends and preparing for it – are better than simply reacting and 
adapting to information received or results of public consultation, and that more 
formalised innovation governance and general strategies to follow are needed. The need 
for communication mainly between Industry and regulators but also with many other 
stakeholders was emphasised. Adequate resources and the difficulties of prioritisation 
were recognised as challenges for regulatory work on the safety assessment of 
innovations. Precautionary measures may be applied to regulate unknowns such as the 
safety of innovations. 
                                           
(35) As illustrated e.g. by the evolution of soaps and detergents, which after 1940 contained increasing amounts 
of non-biodegradable ingredients, limited in the 1970s by legal requirements concerning biodegradability 
https://www.sciencedirect.com/science/article/pii/S0304415700000137 
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3.1.2.2 Needs for becoming aware of innovations 
Becoming aware of innovations that may need the closer attention from regulators 
requires horizon-scanning activities as well as communication and interaction between 
regulators, Industry and other relevant stakeholders. 
Horizon scanning(36) requires both working time and resources. One option is to entrust 
this work to specific forward-looking regulatory units or task forces, or to units that 
specifically deal with innovations (this approach is used in the Republic of Korea). While 
specific tools may facilitate horizon-scanning activities, networking with e.g. R&D 
activities is also important, and regulators also need to communicate among themselves, 
discarding excessive compartmentalisation mentality. 
Communication and interaction between regulators and Industry, e.g. in the form of 
meetings to clarify and improve matters, can become complicated by political issues or 
be confused with lobbying. An alternative is to organise innovation-themed dialogues 
between regulators and public funding agencies (about e.g. SbD or funding), and to 
include one or more organisations representing Industry as the commercial partner 
through which the companies can submit their ideas or questions. For instance, in 
Austria, public innovation-promoting agencies and the Chamber of Commerce meet 
regularly with regulators in a small-scale and informal but effective "brainstorming" 
approach.  
Large-scale meetings with different stakeholders are more likely to serve horizon 
scanning, while smaller and more confidential gatherings can be used to discuss details. 
While some scepticism over the significance of stakeholder consultation was expressed, it 
was recognised that stakeholders (e.g. financial actors, insurance companies, NGOs, 
grass-root organisations, users of the product or occupational organisations) can 
contribute knowledge, resources and social insight and help to concretise accountability 
and responsibility concerning the safety of innovative products. 
3.1.2.3 Needs for being able to assess the hazard/risk of innovations 
Innovation is based on information, and the regulators also need to have this information 
in order to assess the safety of innovative technology and to set priorities. A basic 
problem is that innovators and regulators do not start from the same knowledge point 
and they therefore tend to speak a different language. Consequently, regulators need 
more and better expertise and skills as well as the other necessary resources to deal with 
innovation properly; this in turn requires political will to invest in developing the 
regulators' knowledge and skills by providing the budget, capacity and time needed. Of 
course this needs also to be supported by all actors, e.g. by Industry that could share 
information early, and by science, which could generate the knowledge required and 
develop the tools needed for assessing any innovation. 
In order to cover gaps in the generation of data and information needed for safety 
assessment of innovations, appropriate test methods may need to be developed, which 
again requires resources for the relevant experts as well as appropriate prioritisation of 
the most urgent issues. At the workshop, it was pointed out that metrologists may have 
a lot to say about analytical and test method development in practical terms (e.g. overall 
feasibility, choice of units) and about the standardisation of methods, but communication 
between regulators and metrologists does not currently work well. Regarding chemicals 
and materials, the use of grouping and read-across and QSAR (quantitative structure–
activity relationship) models helps to make efficient use of the existing data and 
information in safety assessment; however, for new materials, for instance NMs, such 
techniques may require further development and adaptation to become acceptable in the 
regulatory context. To look at the big picture of the potential impacts of introducing an 
                                           
(36)  OECD: "a technique for detecting early signs of potentially important developments through a systematic 
examination of potential threats and opportunities, with emphasis on new technology and its effects on the 
issue at hand", https://www.oecd.org/site/schoolingfortomorrowknowledgebase/futuresthinking/ 
overviewofmethodologies.htm 
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innovative product on the market, e.g. socio-economic impact analysis and strategic 
environmental assessment can be applied. Regarding products that may release a 
chemical in the environment, population-level biomonitoring and epidemiological data 
("cocktail effects") would also come useful. 
In addition to becoming aware of upcoming innovations as discussed above, regulators 
also need to receive more extensive, even if yet uncertain, information about these 
innovations well in advance of intended market launch, preferably straight from the 
innovators/Industry. Such information includes details such as how the innovation differs 
from existing products, what the specifications are, details on possible uses (since actual 
exposure data may not be available yet), and any factors that could be relevant for the 
assessment of potential adverse outcomes. All in all, open and honest dialogue with 
Industry that is developing an innovative product is desirable from an early stage, but 
pre-market notification or registration obligations are stronger instruments than 
communication; they also balance the responsibility and testing burdens better between 
regulators (public funding) and Industry (private funding).  
Regulators need resources and time for going through and properly digesting the 
available and provided data and information and for considering the options of dealing 
with each innovation within the existing regulatory framework. An example of real-life 
difficulties is the case of heat-not-burn tobacco products entering the market; from the 
regulatory point of view, discussion has been needed on whether they can be placed in 
an existing regulatory product category (tobacco products) or they need a new category 
or definition. 
Regulations concerning safety assessment should be built to be flexible, so that their 
implementation is possible when new types of materials or products appear without a 
continuous need to change the legal text, which is a time-consuming process for 
regulators and often seen as an obstacle to innovation by Industry. In order to achieve 
this, it is crucial that innovators are heard from the beginning of the process of drafting 
such regulations, although the prevention of conflicts of interest may require that they 
are involved through an intermediate. In the EU, stakeholders' consultations include 
representatives of industry associations and are held not only while drafting a legal act 
but also while its implementation and impact are monitored. "Cross-fertilisation" type 
learning across different regulations is also needed, as an innovative application may 
initially appear in a specific sector (e.g. food) and only later in others (e.g. cosmetics). In 
the absence of legislation or regulation that properly addresses a particular innovation, it 
should be possible to require the developers to provide screening-level data for safety 
assessment. 
In order to improve communication between regulators and Industry, practical ways to 
share information and reach reciprocal understanding need to be found. Such dialogue 
and sharing of information also requires mutual trust: on the one side, the confidentiality 
of such communication ("use but not disclose") and the intellectual property of Industry 
needs to be guaranteed by regulators; on the other side, the completeness and validity 
of the information provided, especially on safety aspects, needs to be ensured by 
Industry. The required trust takes time to develop. Ideally, a systematic dialogue allows 
the regulators to detect in advance whether current regulations need to be adjusted in 
response to innovative products on their way to the market, and Industry/innovators to 
respectively detect if safety provisions in regulations are likely to prove a challenge for 
placing an innovative product on the market. 
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3.2 Day 2: Tools and barriers for Regulatory Preparedness 
 
3.2.1 Tools supporting Regulatory Preparedness  
3.2.1.1 General remarks 
Certain types of tools, such as dialogue/communication and horizon-scanning activities, 
had already been recognized in the discussions on the preceding topics, as was the need 
of Industry for incentives to engage in dialogue and to share data and information that 
helps to assess and improve the safety of innovative products. There was a strong 
emphasis on tools for communication. These needs can be served by "trusted 
environments", platforms in which the innovators and Industry feel they can make 
inquiries and share information with regulators while protecting their intellectual property 
and financial investments. 
3.2.1.2 Tools for awareness 
Various kinds of horizon scanning and foresight tools and early warning systems can help 
regulators to become aware of innovations that require particular attention. However, 
this also requires identifying indicators or critical factors (triggers) that should draw such 
attention. While trusted environments can encourage innovators/Industry to forewarn 
regulators of innovative products that may enter the market in the near future and may 
not be properly covered by current regulations, regulators also need to actively search 
for such information. Networking (such as visiting the local industry, or exchanges with 
patent authorities), attending relevant technological conferences and workshops (also 
technical workshops between innovators and regulators), performing literature searches, 
utilising tools that scan the internet for emerging subjects or trends, and setting specific 
task forces for these activities can all serve this purpose. So-called "windtunneling" can 
be used to create various future scenarios and then test the performance of the existing 
regulations against them. 
A type of networking recognized as particularly important was the interaction among 
regulators or experts from international organisations (e.g. OECD) and different countries 
(e.g. EU Member States), involving the sharing of experiences and methods. This enables 
everyone to cast a wider net than can be done within any single country or region and to 
learn from the experiences of others. In the basic form of such activity, any new type of 
situation encountered is shared with colleagues, who can then check if they already have 
the same risk on the table or prepare for encountering it. Such sharing can take place 
within various types of expert communities as "tour de table" or "lessons learned" 
exercises. Within the EU, trilateral high-level meetings between ECHA, EFSA and 
European Medicines Agency (EMA) were also suggested37. 
Interactions should be regular and can involve individuals or institutions/groups. Different 
stakeholders can also be involved. Horizon scanning can be performed on general policy 
level (see 3.1.1) or address risk assessment in a specific field of innovation. As examples 
of current approaches, in Finland regular meetings involving all stakeholders are held at 
Ministry level, foresight workshops and stakeholder dialogs (e.g. Nanodialog(38)) are 
organised in Germany, and France employs a task force.  
Choosing the appropriate stage in the development of an innovation (e.g. the Technology 
Readiness Level, TLR) to start communications between regulators, innovators/Industry 
and other stakeholders or e.g. request or require entering the product in a registry (see 
section 2.2.5) is not simple. On the one hand, regulators should have adequate warning 
to prepare for assessing the safety of the innovative product; on the other hand, the 
innovation should have enough shape to give an idea of what it is and how it is going to 
                                           
(37) Such trilateral meeting have indeed taken place.  
(38) https://www.bmu.de/en/topics/health-chemical-safety-nanotechnology/nanotechnology/the-nanodialogue/ 
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be used. Naturally, the information that needs to be provided to regulators should 
correspond with the stage of the innovation in question.  
The other half of the SIA concept, SbD, can improve the awareness of innovators of 
regulatory information requirements and help them both to identify risks of innovative 
products and to produce the appropriate safety-related information and data at 
appropriately early stages of the R&D process. The further development and 
implementation of SbD within Industry and efficient integration with the regulatory safety 
assessment process is therefore desirable. 
3.2.1.3 Tools for risk assessment or management 
If possible, regulators should be provided with open access to information related to the 
safety of innovative products. Whether shared on basis of pre-market obligations (e.g. 
registration or notification), on "trusted environment" type platforms or e.g. in one-on-
one meetings between Industry and regulators, such information needs to be relevant, 
reliable and complete and accompanied by an adequate description of the methods used 
to generate it (preferably standardised or harmonised). This allows regulators to use this 
information as a basis for their assessment of the safety of the innovative product (where 
applicable) or a field of innovation, and helps to develop applicable methodology.  
The sharing of information and data on innovations also involves complex issues such as 
which data are actually needed in each case, what methodology should be used to 
produce it, in what format the data should be provided, and who should have access to 
which data (involving the practical aspects of data sharing and protection). The idea of 
an "iTunes shop of studies" was presented for simplifying the process of finding and 
acquiring access to relevant studies.  
Prioritisation can be served by tools such as the risk ranking toolbox developed by EFSA 
for prioritising microbiological risks(39). 
Best practices guidance on the subject of engaging stakeholders could improve the value 
of stakeholder consultations. Creating networks of experts on specific topics, e.g. as a 
database of experts that authorities can use, could be useful for consultations. Such 
networks can be used for various purposes, though the practical experience to date 
seems to be that the existing expert networks are not used much.  
Tools for dealing with innovations that are already on the market or close to their market 
launch, while sufficient knowledge about their safety is still lacking, depend on the 
sector; some, such as the medical sector, demand stricter, less flexible safety measures 
than others. Tools range from applicable guidance to implementing existing regulatory 
frameworks to developing new legislation. Guidance is fairly easy and quick to change 
and adapt. The revision of a legal act is challenging and time-consuming but binding for 
Industry. Implementing safety assessment and risk management requirements for 
innovative products may entail developing new or adapting existing protocols (e.g. OECD 
TGs) and other tools (e.g. control banding tools). 
 
3.2.2 Barriers for the implementation of Regulatory Preparedness  
3.2.2.1 General remarks 
The identified barriers to implementing regulatory preparedness revolve largely around 
lack of resources, communication, tools, trust or motivation. A clear decision-making 
framework, confidential and useful two-way communication and straightforward tools 
with consistent results would help to make the results of the regulatory process more 
predictable, improving the motivation of Industry to engage. 
                                           
(39) https://www.efsa.europa.eu/en/press/news/150109 
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3.2.2.2 Identified barriers and proposed solutions 
As already pointed out, regulators currently suffer from lack of time and capacity to 
undertake all the work involved, since coping with the current problems leaves little time 
for looking into future challenges. Solving this issue requires the prioritisation of 
regulatory preparedness and political will to grant enough human, technical and financial 
resources for these activities. Policy impact assessment may help policymakers in setting 
priorities. 
In the private sector, out-of-legal-framework (non-regulatory) safety assessment of 
novel products may be performed in large companies, but small and medium-sized 
enterprises (SMEs) involved in innovative activities may not have the mind set or 
resources to consider safety or regulatory aspects. Particularly the SMEs often focus on 
the commercial aspects of their products, and starting the development process of an 
innovative product and then selling it to a larger company is a common business model; 
at this initial stage of the innovation process, safety may not be a main concern. SMEs 
may also take significant occupational risks in order to produce a sellable innovation, 
though the final product as such may very well be safe. Making it easier particularly for 
SMEs to consider both occupational and final product safety, the relevant regulations and 
how regulation is going to evolve e.g. by actively promoting awareness can help, and 
implementing the SbD concept in innovation processes may play a part in this. 
There are also sectors with little or no current specific regulation and therefore little 
incentive for Industry to think of the safety aspects of innovations (example: 3-D 
printing). Since it is in the interest of Industry that their products do not draw negative 
public attention in the form of safety issues, it should be possible to start discussions 
with such sectors. Some sectors also lack industry associations able to act as 
intermediators or facilitators in such discussions, in building trust and in sharing 
information.  
Research concerning innovations is generally not risk-focused, and research programmes 
are rarely focused on regulatory questions, unless this is included in their purpose (e.g. 
NANoREG, ProSafe). While regulators may request and fund safety-focused research 
from contractors (see section 3.1.1), project bureaucracy also tends to mean that it 
takes a long time to set up a research project and then produce the data or information 
needed. As a remedy, appropriate funding for risk-focused studies should be secured, 
and smaller projects that are quicker to start and carry through should be considered for 
answering specific questions. 
Mistrust among the involved stakeholders covers both intellectual property issues and 
lack of trust in the information provided by Industry, in the methodology used and the 
robustness of the data obtained. Access to sensitive information is always problematic, 
particularly if there is no clear incentive for Industry to share this information, e.g. with 
regulators. As already pointed out, regulators need instruments for requiring certain 
information from Industry (as e.g. under REACH), but to properly serve Regulatory 
Preparedness, such information should be received through voluntary communication 
well before the process to obtain market approval starts. Trust needs to be built up 
incrementally, ensuring the confidentiality of the communications and the added value of 
communication and proper consideration of safety regulations to Industry, while 
familiarity and a history of safe use improve the confidence of regulators and the public 
in the safety of a certain innovation. In general, systematic ways of communication are 
needed. 
Unclear and/or inapplicable guidance and instructions provided by the authorities are a 
barrier to Industry producing the required information or data relevant to the safety 
assessment of an innovation. To solve this issue, regulators need to be able to provide 
and commit to providing clear and useful guidance, including official answers to 
questions. Since regulatory decisions are necessarily based also on e.g. socioeconomic 
considerations and scientific progress, there are elements of uncertainty in the 
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enforcement and evolution of regulations which can also affect Industry's motivation to 
engage in dialogue.  
Demonstrating the validity of the data produced and provided is problematic when there 
are not yet any agreed standards or validated methods for a particular type of innovative 
product. The development of TGs and instrumentation and the appropriate validation of 
protocols require time and appropriate resources for authorities, standardisation 
organisations and Industry. 
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4 Conclusions 
 
Regulatory Preparedness was defined at the workshop as the regulators' timely 
awareness of innovations and the regulator's actions to check whether present legislation 
covers all safety aspects of each innovation, including initiating revision of the legislation 
as appropriate. Achieving Regulatory Preparedness for innovations based on 
nanotechnology requires a continuous proactive combination of interconnected activities: 
Awareness of innovations: achieved through the use of technology foresight tools, 
horizon scanning, internet searches, trend-watching, etc. as well as the constant dialogue 
with stakeholders mentioned below. 
Dialogue: interaction with different stakeholders (Industry, NGOs, experts, academia, 
etc.), bilateral dialogue between regulators and innovators in trusted environments (i.e. 
platforms in which the innovators and Industry feel they can make inquiries and share 
information with regulators while protecting their intellectual property and financial 
investments), and dialogue among regulators representing different disciplines and 
regulatory domains within e.g. the EU and OECD. 
Knowledge building: gathering information about innovation through registration and 
pre-market information requirements; open access to safety-relevant data; data sharing 
across regulatory domains; development of strategies for balancing confidentiality and 
transparency. 
Methodology enhancement and optimisation: overcoming methodological hurdles in 
generating safety-relevant data by e.g. networks bridging regulatory domains and 
Industry, rather than by separate actors; development of harmonized test methods 
specific for new technologies; exploration of alternative methods, such as grouping and 
read-across, and new approaches such as toxicogenomics. 
Reflection: learning and knowledge-sharing across domains and regulations, adapting 
processes as necessary.  
Consideration of additional factors or procedures: potential need for dedicated 
organisations or task forces to deal with innovations and disseminate information across 
domains and among stakeholders; fair balancing of the financial burden of data 
generation and safety assessment between Industry, regulators and e.g. public health 
institutes; importance of risk communication to keep the society informed of advances in 
knowledge. 
 
In order to implement Regulatory Preparedness for nanotechnology innovations as a part 
of the Safe Innovation Approach (SIA) pursued by NanoReg2, a "road map" of actions of 
different time scales and levels of formal acceptance was outlined: 
 
Near-term 
 Acceptance of Safe-by-Design (SbD) by regulators:  
o Early engagement of regulators in product design process 
o Industry addresses hazard and exposure concerns early in the product 
design process 
 Establishment of databases for valid (reliable) data 
 Establishment of registries 
 Pre-consultations with the industry (individual products) 
 Prioritisation of the development of the most needed experimental protocols and 
guidance  
 Broader stakeholder meetings 
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Mid-term 
 Development of OECD Test Guidelines for nanomaterials 
 Development of other general guidance specific to nanomaterials 
 Exploit the EU Nanomedicine Characterisation Laboratory (NCL) as a model for a 
(nano)innovation network 
o Cooperation between regulators and Industry 
o Protocol development 
o Early screening for the industry (not only medical) 
o Open to Industry use 
 Identification of the most promising protocols and methods in development 
 
Formal regulatory developments 
 Moving from guidance to legislation 
 Where required, shifts in definitions and regulatory requirements for data 
 Finalisation of protocols 
 Validation and acceptance of alternative methods 
 Development of a more effective data generation process that benefits all 
o Nanospecific tiered testing or intelligent testing strategies 
o Valid protocols for these strategies 
 
The ideas presented at the workshop and the outcomes will feed back into the NanoReg2 
project. 
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List of abbreviations 
AOP  adverse outcome pathway 
BNCT  (OECD) Working Party on Biotechnology, Nanotechnology and Converging 
Technologies 
ECHA  European Chemicals Agency 
EFSA  European Food Safety Authority 
EHS  Environment, Health and Safety 
EMA  European Medicines Agency 
EU  European Union 
GLP  Good Laboratory Practice 
HSE  Health, Safety and Environment 
HTS  High Throughput Screening 
KET  Key Enabling Technology 
MNM  manufactured nanomaterial 
MS  (EU) Member State 
NGO  non-governmental organisation 
NM  nanomaterial 
OECD  Organisation for Economic Co-operation and Development 
R&D  research and development 
REACH  Regulation (EC) No 1907/2006 of the European Parliament and of the 
Council of 18 December 2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals  
RIVM  (Dutch) National Institute for Public Health and the Environment 
RP  Regulatory Preparedness 
SbD  Safe-by-Design 
SIA  Safe Innovation Approach 
SME(s)  small and medium-sized enterprise(s) 
TG  (OECD) Test Guideline 
WPMN  (OECD) Working Party on Manufactured Nanomaterials 
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Annexes 
 
Annex 1. Background document 
Dynamic advances in nanotechnology innovation continuously introduce more 
sophisticated nanomaterials with novel properties and potentially novel risks. Discussions 
on potential health risks of nanomaterials demonstrate that conventional information 
requirements for regulatory safety assessment and risk management approaches may 
not cover all aspects relevant for nanomaterials. Therefore, the required regulatory 
standard information is not always sufficient to demonstrate safety. In addition, 
nanotechnology evolves at a much faster pace than regulation, which thus lags behind in 
addressing safety issues. In the Safe Innovation Approach (SIA), under development 
within the EU project NanoReg2, we look for ways to enhance the ability of all 
stakeholders to create robust, yet flexible processes that can be quickly adapted to new 
information needs and that can use information resources proactively for a more efficient 
assessment of the safety of innovative nanomaterials and nanoproducts. SIA should lead 
to a resilient process which has the ability to anticipate, learn about and adapt to 
technological innovations.  
Regulators are an important group of stakeholders in this system. They need to 
anticipate the appearance on the market of new materials and products that are 
insufficiently, or not at all, covered by present legislation and guidelines. The present 
pace of innovation makes it challenging for regulators to anticipate such developments. 
For this reason, we introduce the concept of Regulatory Preparedness as part of SIA. 
 
 
 
Workshop objectives 
The objective of this workshop is to openly discuss with various regulatory bodies the 
regulatory challenges posed by nanotechnology innovations. The objectives of the 
discussions include (random order): 
 Inventory of views on the role of safety policies and legislation in innovation 
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 Common understanding of the Regulatory Preparedness concept 
 Awareness of and consensus on the need for Regulatory Preparedness 
 Insight into regulators' needs to be prepared for innovations 
 Identifying tools needed to achieve Regulatory Preparedness 
 Insight into the incentives and barriers surrounding Regulatory Preparedness 
 
Background information 
Innovation is an important tool to boost economic growth and sustainable development, 
and one of the most important drivers of societal prosperity. To fully achieve such 
desirable objectives, safe innovation is needed. However, the tools and information 
necessary for assessing product safety often lag behind the dynamic pace of innovation 
and thus are unavailable. In the case of manufactured nanomaterials (MNMs), substantial 
research efforts have given insights into possible differences in toxicity and exposure 
compared to conventional chemicals. For safety assessment purposes, e.g. some of the 
OECD test guidelines need to be adapted for MNMs, and the data requirements in 
legislation should be tailored to address nanospecific safety concerns.  
In this workshop, ideas on how regulators can keep up with the exponential growth of 
innovations will be searched for. The input from the workshop will be used by the 
NanoReg2 project to help to establish a practical Regulatory Preparedness concept. 
 
Why do regulators need to be prepared for innovations? 
Regulatory Preparedness is needed for regulators and policymakers to be able to keep up 
with the exponential pace of technological change and to ensure the human and 
environmental safety of innovative emerging technologies, such as (novel) MNMs and 
products containing them. 
The Regulatory Preparedness (RP) concept under development by NanoReg2 aims to 
improve the foresight of regulators and thus facilitate the development of adaptable 
(safety) legislation that can keep up with the pace of knowledge generation and 
innovation in the field of nanotechnology. To achieve this, regulators need to be aware of 
new materials, technologies and innovations at an early stage of the innovation process 
and to keep track of whether current legislation address all nano-relevant aspects of 
innovation to ensure human and environmental safety. 
 
What are the challenges with legislation for innovations? 
Since technological innovation is a constant and dynamic process, it presents a challenge 
for legislation, often resulting in a significant gap in time between the innovation and the 
development of suitable legislation. An example of such a disconnection are self-driving 
vehicles. From an innovation perspective, such vehicles are a good alternative transport 
that uses electric energy and has the ability to reduce traffic congestion and number of 
accidents, providing a new outlook for mobility. From the regulatory perspective, 
however, new legislation must be developed to support the safety testing and operation 
of self-driving vehicles. Further related issues such as vehicle registration, tax, licensing, 
insurance, traffic regulations, equipment standards, and vehicle owner or operator 
responsibilities and liabilities also need to be resolved, possibly by amending the current 
legislation in force. 
Nanotechnology is another field where innovation happens at a faster pace than the 
generation of adequate and sufficient knowledge for addressing the safety of these 
materials and products. From the innovation perspective, nanotechnology is a key 
enabling technology that has revolutionized multiple industrial sectors such as electronic 
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products and applications, and the manufacturing sector, where stronger, more durable 
and lighter materials are now being developed. The foreseen market growth for MNMs 
and products containing them is exponential (Ramsden, 2016), with a substantial 
number of new MNM applications ranging from cosmetics to automotive industry and 
solar panels (RIVM, 2015). From the regulatory perspective, the current various 
legislations for conventional chemicals may not be sufficient to assess the safety for 
MNMs. In the EU, however, the basic viewpoint is that MNM-related risks are in essence 
covered by the current legislative frameworks, with some additional regulatory elements 
(e.g. data requirements) to be included in future to address nanospecific concerns (RIVM, 
2015). Are there other ways for safety research and legislation to keep up with the fast 
pace of innovation? 
 
How can regulators keep up with innovations? 
In order to keep up with innovation, the role of safety regulators needs to evolve from a 
reactive to a proactive one. This means that even though, in many instances, the 
industry is responsible for the safety of their products, regulators need to actively stay 
informed on innovations and be engaged in dialogue with innovators and industry. 
Regulators and industry should share knowledge on how to deal with new developments 
and with the limited insight into how nanospecific characteristics influence human and 
environmental toxicity. Regulators may also support efforts to translate this knowledge 
into policy by engaging with policy makers in an efficient and timely manner. 
 
Strategies and tools in literature 
In the literature, a number of strategies and tools are mentioned that may support giving 
shape to Regulatory Preparedness (RP): 
 Foresight – anticipating the long-term implications of nanotechnologies, sorting 
through certainties and uncertainties to generate scenarios, public deliberation, 
risk analysis to connect decision-making and governance resulting in effective 
policy (Barben 2007, Guston 2007, Guston 2010), imagining alternative futures 
and testing courses of action before deploying them (Fuerth 2009, Wender et al. 
2012), use of “reasonable worst-case” scenarios as temporary fillers for data gaps 
(Philbrick 2010), technology assessment, horizon scanning, and generating vision 
statements (Stilgoe et al. 2013). A proposal for a Foresight System for MNMs was 
made by Micheletti and Sips (2016) in the NANoREG project Deliverable 6.1. 
 Engagement of various stakeholders, including those carrying out fundamental 
research, market players, regulators and policy makers (Barben 2007, Guston 
2010). Gathering information from a wide range of experts along the MNM life 
cycle, from upstream research to downstream management, to become more 
aware of and prepared for nanotechnologies (Beaudrie et al. 2013). 
 Integration of broader considerations into R&D contexts (Hussain et al. 2000, 
Barben 2007, Guston 2010, Wender et al. 2012). Social and natural scientists 
working together to develop the capacity of nanoscientists to reflect on the wider 
societal dimensions of their work. 
 Boundary spanning linking together different types of stakeholders to bridge gaps 
between different actors and communities in ways that help stakeholders to come 
together while simultaneously allowing “divergent interests and unique social 
norms to persist” (Michelson 2013, Michelson 2017). 
 Networked Governance – organizing the government for more effective 
management of complex issues (Fuerth 2009, Fuerth 2012). 
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 Feedback for an ongoing evaluation, reassessment, and recalibration of policies, 
to monitor and adjust policy, maintain accountability and self-synchronization, 
and promote resilience and rapid learning (Fuerth 2009, Fuerth 2012). 
 The ensemble-ization of different research fields such as technology assessment, 
public engagement and laboratory studies could provide “integrated” information 
for modulating nanotechnology innovations (Barben 2007, Guston 2010). 
 The incorporation of anticipatory life cycle assessment within Regulatory 
Preparedness is mentioned as a tool to draw attention to end-of-life 
considerations (environmentally problematic processes) in the life cycle of 
nanotechnology (Renn and Roco 2006, Philbrick 2010, Wender et al. 2012). 
 Regulatory Preparedness is an incremental, iterative and continuous effort 
(Ozdemir et al. 2011).  
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Annex 2. Workshop agenda 
 
Agenda 
NanoReg2 Workshop on Regulatory Preparedness for Innovation in 
Nanotechnology 
Jointly organised by RIVM and the JRC 
 
 
Dates  October 5‒6, 2017 
Venue  Casa Don Guanella, Ispra (VA), Italy 
 
Day 1  5th of October, 2017  
8.30-9.00 Registration  
 Welcome and setting the scene Chair: Juan Riego Sintes (JRC) 
9.00 Welcome by workshop hosting 
institution  
Introduction to NanoReg2 
Scope and objectives of the 
workshop 
Elke Anklam (JRC) 
 
Emeric Frejafon (INERIS)  
Lya Soeteman-Hernández (RIVM)  
 Regulatory context Chair: Juan Riego Sintes (JRC) 
9.25 The need for Regulatory 
Preparedness (Strategic foresight 
and implications for European 
research and innovation policies) 
Georgios Katalagarianakis (DG 
RTD) 
9.55 Nanomaterials in food: regulation 
and innovation 
Takis Daskaleros (DG Sante) 
10.25 An example of being prepared for 
innovations in food 
Reinhilde Schoonjans (EFSA) 
10.55-
11.15 
Coffee break  
11.15 OECD’s approach to the safety of 
nanomaterials: lessons learned for 
regulatory preparedness and future 
innovation 
Mar Gonzalez and Peter Kearns 
(OECD / WPMN) 
11.45 Ongoing French regulatory or pre-
regulatory initiatives 
Damien De Geeter (Ministère de la 
Transition écologique et solidaire) 
12.15 Safe Innovation Approach (SIA) 
 
Lya Soeteman-Hernández (RIVM) 
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12.45-
14.00 
Lunch break   
14.00 Introduction to the break-out groups  Lya Soeteman-Hernández (RIVM) 
14.15 Breakout groups Chairs: Susan Dekkers, Monique 
Groenewold, Lya Soeteman-
Hernández (RIVM), Andrea Haase 
(BfR) 
Rapporteurs: Agnieszka Mech, Paula 
Jantunen, Kirsten Rasmussen, Juan Riego 
Sintes (JRC) 
14.15 Break-out group discussions 
1. How do regulators currently 
deal with innovations 
2. What do regulatory risk 
assessors need to be 
prepared for innovations 
 
15.00-
15.30 
Coffee break  
15.30 Break-out group discussions 
continue  
 
17.00 Debrief from breakout groups' 
rapporteurs and chairs, and 
plenary discussion 
Chair: Monique Groenewold 
(RIVM) 
17.30 Closing, group photo and transfer 
to the hotels (ca. 18) 
 
 
Day 2 6th of October, 2017 
8.45 Welcome  
Wrap-up of day 1 
Juan Riego Sintes (JRC) 
Monique Groenewold (RIVM) 
 Tools for regulatory 
preparedness 
Chair: Monique Groenewold 
(RIVM) 
9.00 Framework of policy assessment of 
emerging technologies 
Steffi Friedrichs (OECD / BNCT) 
9:30 Impact of precautionary regulation 
on innovation processes 
David Azoulay (CIEL) 
10.00 NANoREG Foresight System Christian Micheletti (EcamRicert) 
10.30 White Paper implications for 
Regulatory Preparedness 
Tom van Teunenbroek (Dutch 
Ministry of Infrastructure and the 
Environment)  
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10.45-
11.15 
Coffee break  
 Breakout groups Chairs: Monique Groenewold, Lya 
Soeteman-Hernández (RIVM), 
Emeric Frejafon (INERIS), Andrea 
Haase (BfR) 
Rapporteurs: Agnieszka Mech, Paula 
Jantunen, Juan Riego Sintes (JRC), Karl 
Höhener (TEMAS) 
11.15 Break-out groups discussion 
3. Tools supporting regulatory 
preparedness  
4. Identify barriers for the 
implementation of the 
regulatory preparedness 
concept 
 
12.45-
13.45 
Lunch break   
13.45 Debrief from break-out groups by 
rapporteurs and chairs, and 
plenary discussion 
Chair: Monique Groenewold 
(RIVM) 
 
14.10 Recommendations and way 
forward. Panel 
Reflections by: 
Emeric Frejafon (INERIS), Kenneth 
Moss (US-EPA), Monique 
Groenewold (RIVM), Juan Riego 
Sintes (JRC), Phil Sayre (nanoRisk 
Analytics) 
14.30 Closing  
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Annex 3. Break-out group discussion templates 
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Annex 4. Participant list 
Last Name 
First 
Name 
Organisation 
ANKLAM Elke Joint Research Centre 
AZOULAY David Center for International Environmental Law 
(CIEL), Switzerland 
BACHMANN Volker Federal Institute for Occupational Safety and 
Health (BAuA), Germany 
BAE Hee 
Kyung 
TO21 Co. Ltd, South Korea 
BARAT BAVIERA Jose 
Manuel 
Universitat Politècnica de València, Spain 
BARRERO Josefa Joint Research Centre 
BARTCZAK Dorota LGC, UK 
BIESA María del 
Pilar 
Agency for Consumer Affairs, Food Safety and 
Nutrition (AECOSAN), Spain 
BYGRAVES Julie Department of Environment Food and Rural 
Affairs, UK 
CRAWFORD Joanne Institution of Occupational Medicine (IOM), UK 
DASKALEROS Takis European Commission (DG SANTE) 
DE GEETER Damien Ministère de la Transition écologique et 
solidaire, France 
DEKKERS Susan RIVM, the Netherlands 
DŁUŻEWSKA Marta National Institute of Public Health – National 
Institute of Hygiene, Poland 
FLAMENT Guillaume Nanotechnology Industries Association, Belgium 
FREJAFON Emeric INERIS, France 
FRIEDRICHS Steffi OECD 
GALEA Karen Institution of Occupational Medicine, UK 
GIANNINI Luca Pirelli Tyre SpA, Italy 
GONZALEZ Mar OECD 
GOTTARDO Stefania Joint Research Centre 
GROENEWOLD Monique RIVM, the Netherlands 
HAASE Andrea Federal Institute for Risk Assessment (BfR), 
Germany 
HABER Bernd BASF SE, Germany 
HEYVAERT 
 
Els Federal Public Service Health, Food Chain 
Security and Environment, Belgium  
HÖHENER Karl TEMAS AG, Switzerland 
HOEVELER Arnd Joint Research Centre 
HOLMQVIST Jenny European Chemicals Agency (ECHA)  
IOANNOU 
PAPAYIANNI 
Elena State General Laboratory, Cyprus 
JANTUNEN Paula Joint Research Centre 
JEDLIČKOVÁ Michaela Ministry of Agriculture, Czech Republic 
JENSEN Keld 
Alstrup 
National Research Centre for the Working 
Environment (NRCWE), Denmark 
JESSE Anke Federal Ministry of the Environment (BMU), 
Germany 
KATALAGARIANAKIS Georgios European Commission (DG RTD) 
KEARNS Peter OECD 
LAVOIGNAT Melanie Ministère de l'Agriculture et de l'Alimentation, 
France 
LODI Federica European Food Safety Authority (EFSA) 
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Last Name 
First 
Name 
Organisation 
MANNONEN Leena Ministry of Agriculture and Forestry, Finland 
MCCARRON Eileen State Laboratory, Ireland 
MCDONALD Karl Food Safety Authority of Ireland 
MECH Agnieszka Joint Research Centre 
MICHELETTI Christian ECAMRICERT Srl, Italy (now TEMAS AG, 
Switzerland) 
MOSS Kenneth U.S. Environmental Protection Agency (EPA), 
USA 
OJEA JIMENEZ Isaac Joint Research Centre 
POGANY Alexander Ministry for Transport, Innovation and 
Technology (BMVIT), Austria 
QUIROS PESUDO Laia Joint Research Centre 
RASMUSSEN Kirsten Joint Research Centre 
RIEGO SINTES Juan Joint Research Centre 
RINCON  Ana Maria European Food Safety Authority (EFSA) 
RODRÍGUEZ LLOPIS Isabel GAIKER-IK4, Spain 
SAYRE Phil nanoRisk Analytics LLC, USA 
SCHOONJANS Reinhilde European Food Safety Authority (EFSA) 
SIMONEAU Catherine Joint Research Centre 
SOETEMAN-
HERNÁNDEZ 
Lya RIVM, the Netherlands 
SOKULL-KLÜTTGEN Birgit Joint Research Centre 
SPIRLET Christine International Zinc Association 
TENTSCHERT Jutta  Federal Institute for Risk Assessment, Germany 
VAN TEUNENBROEK Tom Ministry of Infrastructure and the Environment, 
the Netherlands 
VÁZQUEZ-CAMPOS Socorro LEITAT Technological Centre, Spain 
ZINĀRS Juris Ministry of Agriculture, Latvia 
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GETTING IN TOUCH WITH THE EU 
In person 
All over the European Union there are hundreds of Europe Direct information centres. You can find the 
address of the centre nearest you at: http://europea.eu/contact 
On the phone or by email 
Europe Direct is a service that answers your questions about the European Union. You can contact this 
service: 
- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls), 
- at the following standard number: +32 22999696, or 
- by electronic mail via: http://europa.eu/contact 
FINDING INFORMATION ABOUT THE EU 
Online 
Information about the European Union in all the official languages of the EU is available on the Europa 
website at: http://europa.eu 
EU publications 
You can download or order free and priced EU publications from EU Bookshop at: 
http://bookshop.europa.eu. Multiple copies of free publications may be obtained by contacting Europe 
Direct or your local information centre (see http://europa.eu/contact). 
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